Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease

Controlled Clinical Trials

Volumn 23, Issue 2, 2002, Pages 111-126

  Putt, Mary E ^a   Ravina, Bernard ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Alzheimer's disease; Bias; Crossover design; Parkinson's disease; Study design

Indexed keywords

DONEPEZIL; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; ERROR; EXPERIMENTAL DESIGN; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; PARALLEL DESIGN; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; TIME; TREATMENT OUTCOME;

BIAS (EPIDEMIOLOGY); COGNITION; CROSS-OVER STUDIES; DEMENTIA; EFFECT MODIFIERS (EPIDEMIOLOGY); HUMANS; INDANS; NOOTROPIC AGENTS; PARKINSON DISEASE; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 0036212092     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(01)00207-0     Document Type: Article

References (35)

1. Managing the neuropsychiatric symptoms of Parkinson's disease
2. Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparisons with Alzheimer's disease
3. Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia
4. The nucleus basalis of Meynert in neurological disease: A quantitative morphological study
5. Cholinesterase inhibition for Alzheimer disease
6. Donepezil approved for treatment of Alzheimer disease
7. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: Methodologic considerations
8. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study
9. Donepezil therapy in clinical practice: A randomized crossover study
10. Robust and realistic approaches to carry-over
11. Letter to the editor, on multiperiod crossover studies
12. A critique of recent research on the two-treatment cross-over design
13. An analysis of two-period crossover designs with carry-over effects
14. Review of nonparametric methods for the analysis of crossover studies
15. Crossover trials, degrees of freedom, the carryover problem and its dual
16. A robust analysis of crossover designs using multi-sample generalized L-statistics
17. Design and analysis of intra-subject variability in crossover experiments
18. The two-period change-over design and its use in clinical trials
19. The crossover experiment for clinical trials
20. Using the maximum test statistics in the two-period crossover trial
21. Carryover and the two-period crossover clinical trial
22. The performance of the two-stage analysis of two-treatment, two-period crossover trials
23. Use of two-stage test statistic in two-period crossover trials
24. 2 experimental units
25. Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for designs
26. Investigation of dual-balanced crossover designs for two treatments
27. A critique of recent research on the two-treatment crossover design
28. Carry-over effects in bioequivalence studies
29. Analysis of covariance in parallel-group clinical trials with pre-treatment baselines